
Natco Pharma – Analysis & Next Steps . . . Natco Pharma 8% to 10% up today, 16Feb Why 10% Run - Approval to launch Semaglutide in India. Semaglutide is used to manage chronic weight and treat type-2 diabetes Holding 128 Shares at 1220. Total Loss – 26% Reason for Loss Feb25 - Poor Results posted- 12Feb a. Net Profit declined by 38% b. Formulation exports – 285cr from 600cr c. Export Formulations – 40% of their total revenue Let’s look at fundamentals of the company: • Sales – YoY increasing 4500CR in 2025 • OPM – 40% to 50% OPM - consistently increasing • Profitability – 28% ROE • EPS – YoY increase • Pricing – Green with a PE of 10 • Pharma Companies- 25+ PE • Holdings – 20% - FII and DII Summary – Company needs good news trigger to reduce our losses. Next - EMS, KNR and IREDA Saath mein Seekhenge aur Saath mein Grow Karenge In the past I have shared gems from Banking, IT, Defence, Green Energy, Logistics, Railways, Glass and more The returns are whopping 50+% I am a SEBI registered Research Analyst. My videos are not investment advice. These videos are to help you understand how to select quality stocks. #stockmarket #investment #sharemarketknowledge #stockmarketlearning #invest longterminvestment valueinvestor wealthcreation stockmarketindia stockmarketinvesting indianstockmarket indianstockmarket stockmarketindia stockmarketanalysis longterm longterminvesting sharemarket natcopharma
This post was published on 16th February, 2026 by Ritesh on his Instagram handle "@finskool21 (Ritesh Kumar)". Ritesh has total 364.2K followers on Instagram and has a total of 1.2K post.This post has received 2.6K Likes which are lower than the average likes that Ritesh gets. Ritesh receives an average engagement rate of 0.92% per post on Instagram. This post has received 111 comments which are lower than the average comments that Ritesh gets. Overall the engagement rate for this post was lower than the average for the profile. #investment #sharemarketknowledge #stockmarket #invest #stockmarketlearning has been used frequently in this Post.